LB Pharmaceuticals LBRX 深 沪
等待开盘 11-03 09:30:00 美东时间
16.13
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 16.13
- 总市值 3.24亿
- 52周最高 20.25
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 13.36
- 委 比 0.00%
- 总股本 2010.01万
- 历史最高 20.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 13.36
- 每 手 1
- 风险率 0.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Leerink Partners Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $34
Leerink Partners analyst Marc Goodman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $34.
10-06 19:38
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
LB Pharmaceuticals announced it will present three posters from its Phase 2 NOVA trial of LB-102 for acute schizophrenia at the 2025 ECNP Congress in Amsterdam. The posters include findings on LB-102's effects on cognition, with significant dose-dependent improvements compared to placebo, and its impact on negative symptoms. LB-102 demonstrated robust reductions in PANSS scores and a favorable safety profile, supporting its potential for comprehe...
10-06 12:30
全球生物医药融资超35亿美元 24家创新药企单笔融资破5000万
根据药明康德数据库统计，2025年9月全球生物医药领域共完成135起融资事件，公开披露总额突破35亿美元。其中24家专注创新疗法的企业单笔融资超过5000万美元...
09-27 12:33
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
LB Pharmaceuticals appoints William Kane and Rekha Hemrajani to its Board, adding expertise in finance and commercialization. Their additions aim to support LB-102, a potential first benzamide antipsychotic, through Phase 3 and Phase 2 trials for schizophrenia and bipolar depression. With decades of experience in drug development, Kane and Hemrajani will strengthen the company's strategic growth as it advances its lead product. LB-102's promising...
09-25 12:30
Lightbridge CEO Seth Grae to Participate at the Atlantic Council Nuclear Energy Policy Summit 2025 in New York City
Lightbridge Corporation's CEO, Seth Grae, will participate in a panel discussion titled "Building Reactors, Fuel, and the Workforce" at the Nuclear Energy Policy Summit 2025 hosted by the Atlantic Council. The session will address critical infrastructure and workforce needs in the growing nuclear energy sector. Joining Grae are Katie Aittola, Rafał Kasprów, and Brian Smith. The panel will discuss reactor deployment, fuel innovation, and workforce...
09-18 12:00
生物科技公司LB Pharmaceuticals纳斯达克上市：募资2.85亿美元
雷递网 雷建平 9月14日 生物科技公司LB Pharmaceuticals(LBRX.US)日前在美国纳斯达克上市。 LB Pharmaceuticals发行...
09-14 12:38
Schizophrenia drug developer LB Pharma jumps in trading debut
LB Pharmaceuticals (LBRX) climbed ~26% on Thursday as the New York-based biopharma, focused on developing drugs for neurological conditions such as schizophrenia, opened for trading after raising $285...
09-12 01:41
美股机会日报 | 美国8月CPI符合预期，初请失业金人数创近四年新高！“网红股”Opendoor股价大涨超30%
美国8月CPI符合预期，初请失业金人数创近四年新高！“网红股”Opendoor高层人事巨震，股价应声大涨超30%；阿里巴巴盘前涨近3%，“高德扫街榜”上线当天跃升为国内最大美食榜>>
09-11 21:19
LB Pharmaceuticals(LBRX.US)IPO定价15美元/股 今晚登陆纳斯达克
LB Pharmaceuticals将于周四在纳斯达克上市，股票代码为“LBRX”
09-11 11:53
